BioPharmSignal logoBioPharmSignal

Biotech News

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Absci Corporation (ABSI)Absci CorporationEarnings

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical

Related news

ABSIAbsci Corporation2026-02-24 13:01 EST

Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

ABSIAbsci Corporation2026-07-14 20:05 EST

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

View all latest news

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

ABSIAbsci Corporation2026-07-14 20:05 EST

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

ABSIAbsci Corporation2026-06-24 10:35 EST

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

ABSIAbsci Corporation2026-06-24 10:30 EST

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

ABSIAbsci Corporation2026-05-20 12:00 EST

Absci to Participate in Upcoming Investor Conferences

ABSIAbsci Corporation2026-05-07 20:06 EST

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Stock data

Close
8.30 USD
Market cap
990M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States